MBX Biosciences Earnings Call Transcripts
Fiscal Year 2026
-
The platform enables extended peptide therapies for endocrine and metabolic diseases, with phase III for once-weekly PTH therapy in hypoparathyroidism starting Q3 and a robust obesity pipeline advancing. Key differentiators include urine calcium endpoints and monthly dosing for obesity, with major data readouts expected in Q2 and Q4.
-
FDA alignment for phase three in hypoparathyroidism keeps timelines on track, with strong phase two results and high physician interest in once-weekly dosing. Obesity pipeline advances with MBX 4291 and additional candidates, supported by robust funding into 2029.
-
Significant progress was highlighted across endocrine and obesity programs, with phase III trials for canvorparotide set for Q3 and key obesity data expected in Q4. The proprietary PEP platform underpins a robust pipeline, strong financials, and multiple near-term catalysts.
-
2026 is set as a transformative year with major clinical milestones, including phase III initiation for canvuparatide and key obesity program readouts. Strong financials support pipeline expansion, with robust physician and patient enthusiasm for once-weekly therapies.
-
Multiple clinical milestones are set for 2024, including phase III initiation for canvuparatide and expansion of the obesity pipeline. The PEP platform's unique prodrug and fatty acylation technologies support less frequent, better-tolerated dosing, with strong patient and physician preference for weekly or monthly regimens.
Fiscal Year 2025
-
Strong Phase II data for once-weekly canvuparatide set up a global Phase III in Q3, with a new injector device and high patient enthusiasm. Pipeline includes a once-monthly GLP-1/GIP agonist for obesity and a post-bariatric hypoglycemia program, both with key data in 2026. Cash runway extends into 2029.
-
-
The company is advancing three clinical-stage programs in endocrine and metabolic disorders, highlighted by strong phase II results for once-weekly canvuparatide and robust physician and patient support. Key catalysts are expected in 2026, with funding secured through 2029.
-
Three clinical-stage programs are advancing in hypoparathyroidism, PBH, and obesity, with strong phase II data for Canvuparatide and a focus on once-weekly or monthly dosing. Physician and patient feedback supports category leadership ambitions, and multiple catalysts are expected through 2026.
-
Three clinical-stage programs are advancing, with Canvuparatide showing strong phase II results and high patient retention, and MBX 4291 and Imipexatide targeting large unmet needs in obesity and PBH. Key catalysts are expected in 2026, with major data presentations planned.
-
Positive phase II results for Canvuparatide in hypoparathyroidism support advancement to phase III, while MBX 1416 and MBX 4291 show promising early data in post-bariatric hypoglycemia and obesity, respectively. The company’s strong cash position enables continued pipeline progress and strategic partnerships.
-
Once-weekly candiparatide met the primary endpoint in the AVAIL Phase II trial, with 63% response at 12 weeks versus 31% for placebo, and 79% response at six months in the open-label extension. The therapy was well tolerated, reduced pill burden, improved bone and renal markers, and showed durable efficacy.
-
Precision peptide therapeutics platform advances three clinical-stage programs targeting HP, PBH, and obesity, with key data readouts and regulatory milestones expected in 2024–2026. Lead assets aim to improve dosing convenience, efficacy, and patient outcomes.
-
The company highlighted its PEP platform and lead programs in HP, PBH, and obesity, with key phase 2 data for canvuparatide expected in Q3. The AVAIL trial targets a 48% placebo-adjusted response at 12 weeks, with a strong safety profile and plans for phase 3.
-
A clinical-stage biopharma highlighted its PEP technology and pipeline, including a once-weekly PTH prodrug for hypoparathyroidism with phase II data expected in Q3, a GLP-1 antagonist for PBH entering phase II, and an obesity candidate targeting once-monthly dosing. Top-line results and further clinical milestones are anticipated this year.
-
A precision peptide platform is advancing multiple clinical programs for rare endocrine diseases and obesity, with lead assets showing promising data and near-term milestones. Differentiation centers on dosing convenience, clinical outcomes, and robust financial runway.
-
The company is advancing a precision peptide platform with lead programs in hypoparathyroidism, post-bariatric hypoglycemia, and obesity. Key 2025 milestones include phase II data for Canvuparatide, phase II initiation for MBX 1416, and phase I for MBX 4291, targeting large unmet needs.
-
The company highlighted strong progress across its precision endocrine peptide platform, with its lead candidate canvuparatide fully enrolled in phase II and top-line results expected in Q3 2025. Additional programs for PBH and obesity are advancing, supported by robust funding and a strategic focus on value creation.
-
Multiple clinical programs are advancing, with canvuparatide and MBX 1416 targeting rare endocrine disorders and MBX 4291 aiming to address obesity with improved dosing and tolerability. Key data readouts and trial initiations are expected in 2024 and 2025.
-
MBX is advancing a platform of long-acting peptide therapeutics, with lead asset canvuparatide in phase II for hypoparathyroidism and MBX 1416 moving to phase II for PBH. The company is also developing obesity candidates and is funded into mid-2027.
-
The company presented major progress on its precision endocrine peptide platform, highlighting canvuparatide's phase II trial for hypoparathyroidism, MBX 1416's advancement for post-bariatric hypoglycemia, and a differentiated obesity pipeline. Key data readouts and new trials are expected in 2024.
-
Phase I results for MBX 1416, a once-weekly GLP-1 antagonist for PBH, showed favorable safety, tolerability, and PK/PD profiles in healthy adults, with mostly mild injection site reactions and no serious adverse events. A phase II trial in PBH patients is planned for late 2025.
Fiscal Year 2024
-
A clinical-stage biopharma is advancing a pipeline of long-acting peptide therapeutics, with key programs in hypoparathyroidism, post-bariatric hypoglycemia, and obesity. Major clinical milestones are expected in 2025, supported by strong funding and a differentiated platform.
-
Precision Endocrine Peptides platform advances therapies for hypoparathyroidism, PBH, and obesity, with lead programs showing promising profiles and significant market opportunities. Key catalysts include phase II and I data readouts in 2025 and a strong cash position supporting growth.
-
The company is advancing a pipeline of precision endocrine peptides, with its lead program MBX 2109 in phase 2 for hypoparathyroidism and key data readouts expected in 2025. Strong financials support expansion, and both patient and market interest are high for once-weekly therapies.